449734-00-3

Upstream product

• 101186-10-1 dimethyl (E)-(2-methylpropylidene)succinate 
• 100315-89-7 2-[2-Methyl-prop-(E)-ylidene]-succinic acid diethyl ester 
• 80459-36-5 2-[2-Methyl-prop-(E)-ylidene]-succinic acid dimethyl ester 
• 6543-53-9 2-[2-Methyl-prop-(E)-ylidene]-succinic acid 
• 120369-20-2 (E)-2-(1-isobutylidene)succinic acid 

Downstream Products

• 609360-68-1 2-[2-Methyl-prop-(E)-ylidene]-succinic acid 4-benzyl ester 
• 609360-84-1 N⁴-benzyloxy-N¹-[2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutylidene-succinamide 
• 609360-69-2 (E)-3-[(S)-2-(1H-Indol-3-yl)-1-methylcarbamoyl-ethylcarbamoyl]-5-methyl-hex-3-enoic acid benzyl ester 

Relevant academic research and scientific papers

MMPs inhibitors: New succinylhydroxamates with selective inhibition of MMP-2 over MMP-3

Some ilomastat analogues featuring an isobutylidene group or a 2-substituted indole nucleus were synthesized to evaluate their inhibitory activities against gelatinase A and stromelysin-1. Potent MMP-2 inhibition and good selectivity for that enzyme have

Nitroalkanes and dimethyl maleate as source of 3-alkyl succinic anhydrides and (E)-3-alkylidene succinic anhydrides

Nitroalkanes react with dimethyl maleate giving a tandem Michael addition/elimination of nitrous acid. The obtained (E)-2-alkylidene dimethyl succinates are: (i) reduced to the corresponding 2-alkyl dimethyl succinates which after hydrolysis produce 1,4-dicarboxylic acids that are prone to convert into the corresponding 3-alkyl succinic anhydrides or (ii) hydrolysed to (E)-2-alkylidene-succinic acids that are easily cyclised to (E)-3-alkylidene succinic anhydrides.

NOVEL COMPOUNDS WITH COLLAGENASE-INHIBITING ACTIVITY, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS IN WHICH THESE COMPOUNDS ARE PRESENT

The present invention relates to a novel family of chemical compounds possessing a pharmacological activity, in particular a collagenase-inhibiting activity, a process for the production of these compounds and pharmaceutical compositions in which they are present. According to the invention, these compounds correspond to the general formula: STR1 in which: W represents an amino acid residue selected from the group comprising valine, lysine, norleucine and methionine, andZ represents an amino radical or an alkylamino radical of which the alkyl part, which contains 1 or 2 carbon atoms, is substituted by a phenyl or trifluorophenyl radical,and also include their diastereoisomers and their addition salts with pharmaceutically acceptable acids. The invention is applicable especially in the pharmaceutical industry.